Enfortumab Vedotin Induces Immunogenic Cell Death and Shows Enhanced Preclinical Antitumor Activity When Combined With a PD-1 Inhibitor
RNA-seq (gene expression) · human · 21 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 21 samples: 7 × T24-hNectin4 (untreated) mouse vs 7 × T24-hNectin4 (ADC-treated) mouse vs 7 × T24-hNectin4 (ADC-control) mouseGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE264352_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1102018 and SRA study SRP502679. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 7 samples read as cases, 7 as controls.
How we read this: 3 replicated groups read from 21 sample titles; they account for 21 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8216725 T24-hNectin4 (untreated) mouse 1 T24-hNectin4 (untreated…
- GSM8216726 T24-hNectin4 (untreated) mouse 2 T24-hNectin4 (untreated…
- GSM8216727 T24-hNectin4 (untreated) mouse 3 T24-hNectin4 (untreated…
- GSM8216728 T24-hNectin4 (untreated) mouse 4 T24-hNectin4 (untreated…
- GSM8216729 T24-hNectin4 (untreated) mouse 5 T24-hNectin4 (untreated…
- GSM8216730 T24-hNectin4 (untreated) mouse 6 T24-hNectin4 (untreated…
- GSM8216731 T24-hNectin4 (untreated) mouse 7 T24-hNectin4 (untreated…
- GSM8216732 T24-hNectin4 (ADC-treated) mouse 1 T24-hNectin4 (ADC-treat…
- GSM8216733 T24-hNectin4 (ADC-treated) mouse 2 T24-hNectin4 (ADC-treat…
- GSM8216734 T24-hNectin4 (ADC-treated) mouse 3 T24-hNectin4 (ADC-treat…
- GSM8216735 T24-hNectin4 (ADC-treated) mouse 4 T24-hNectin4 (ADC-treat…
- GSM8216736 T24-hNectin4 (ADC-treated) mouse 5 T24-hNectin4 (ADC-treat…
- GSM8216737 T24-hNectin4 (ADC-treated) mouse 6 T24-hNectin4 (ADC-treat…
- GSM8216738 T24-hNectin4 (ADC-treated) mouse 7 T24-hNectin4 (ADC-treat…
- GSM8216739 T24-hNectin4 (ADC-control) mouse 1 T24-hNectin4 (ADC-contr…
- GSM8216740 T24-hNectin4 (ADC-control) mouse 2 T24-hNectin4 (ADC-contr…
- GSM8216741 T24-hNectin4 (ADC-control) mouse 3 T24-hNectin4 (ADC-contr…
- GSM8216742 T24-hNectin4 (ADC-control) mouse 4 T24-hNectin4 (ADC-contr…
- GSM8216743 T24-hNectin4 (ADC-control) mouse 5 T24-hNectin4 (ADC-contr…
- GSM8216744 T24-hNectin4 (ADC-control) mouse 6 T24-hNectin4 (ADC-contr…
- GSM8216745 T24-hNectin4 (ADC-control) mouse 7 T24-hNectin4 (ADC-contr…
- GSE260599 Anti-tumor activity of a novelLAIR1antagonist in combination with anti-PD-1to treat collagen-rich solid tumors 61 samples shares pd-1, activity
- GSE218241 PIKfyve inhibition synergizes with Cisplatin to provoke antitumor immunogenicity in melanoma by alleviating lysosomal degradation of STING 18 samples shares immunogenic, antitumor
- GSE242839 PD-1 is induced on tumor-associated macrophages in obesity to directly restrain anti-tumor immunity 29 samples shares pd-1
- GSE333858 PD-1 regulates latent effector differentiation of thymic cytotoxic CD8+ T cells 74 samples shares pd-1
- GSE214631 Targeting tumor-intrinsic N7-methylguanosine tRNA modification inhibits MDSC recruitment and improves anti-PD-1 efficacy 14 samples shares pd-1
- GSE135798 VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers 10 samples shares pd-1
- GSE244511 KDM6A Regulates Immunogenicity of Multiple Myeloma (RNA-seq) 40 samples shares immunogenic
- GSE255548 EZH2 INHIBITION ENHANCES T CELL IMMUNOTHERAPIES BY INDUCING LYMPHOMA IMMUNOGENICITY AND IMPROVING T CELL FUNCTION (RNA-Seq) 35 samples shares immunogenic
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.